NVAX Novavax, Inc. Stock Quote

NVAX [NASD]

Index	-	P/E	-	EPS (ttm)	-9.25	Insider Own	0.20%	Shs Outstand	73.03M	Perf Week	14.57%
Market Cap	15.19B	Forward P/E	6.94	EPS next Y	30.21	Insider Trans	-47.52%	Shs Float	69.32M	Perf Month	64.04%
Income	-615.10M	PEG	-	EPS next Q	-3.63	Inst Own	58.20%	Short Float	8.38%	Perf Quarter	3.41%
Sales	919.50M	P/S	16.51	EPS this Y	-32.00%	Inst Trans	9.97%	Short Ratio	1.64	Perf Half Y	81.98%
Book/sh	14.23	P/B	14.74	EPS next Y	603.40%	ROA	-40.60%	Target Price	258.00	Perf Year	371.93%
Cash/sh	27.59	P/C	7.60	EPS next 5Y	0.00%	ROE	-125.70%	52W Range	43.60 - 331.68	Perf YTD	88.04%
Dividend	-	P/FCF	26.39	EPS past 5Y	9.50%	ROI	-38.00%	52W High	-37.52%	Beta	1.56
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	67.30%	Gross Margin	-	52W Low	375.28%	ATR	14.94
Employees	791	Current Ratio	1.90	Sales Q/Q	3072.20%	Oper. Margin	-65.50%	RSI (14)	65.03	Volatility	7.79% 8.26%
Optionable	Yes	Debt/Eq	0.44	EPS Q/Q	-423.70%	Profit Margin	-66.90%	Rel Volume	3.51	Prev Close	209.68
Shortable	Yes	LT Debt/Eq	0.33	Earnings	May 10 AMC	Payout	-	Avg Volume	3.54M	Price	207.22
Recom	2.20	SMA20	26.27%	SMA50	14.46%	SMA200	35.24%	Volume	9,778,979	Change	-1.17%

May-12-21

Downgrade

JP Morgan

Overweight → Neutral

$285 → $161

Dec-14-20

Initiated

Jefferies

Buy

$200

Aug-06-20

Reiterated

H.C. Wainwright

Buy

$132 → $290

Aug-05-20

Upgrade

JP Morgan

Neutral → Overweight

$275

Aug-05-20

Downgrade

Ladenburg Thalmann

Neutral → Sell

$105

Jul-16-20

Reiterated

H.C. Wainwright

Buy

$101 → $132

Jul-08-20

Downgrade

Ladenburg Thalmann

Buy → Neutral

$50 → $105

Jun-29-20

Reiterated

H.C. Wainwright

Buy

$50 → $101

Jun-29-20

Reiterated

B. Riley FBR

Buy

$74 → $106

Jun-05-20

Upgrade

JP Morgan

Underweight → Neutral

$46

May-28-20

Reiterated

B. Riley FBR

Buy

$53 → $61

May-12-20

Reiterated

H.C. Wainwright

Buy

$33 → $50

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$24 → $33

Nov-27-19

Resumed

B. Riley FBR

Buy

$12

Aug-14-19

Reiterated

H.C. Wainwright

Buy

$10 → $17

Feb-28-19

Downgrade

Piper Jaffray

Overweight → Underweight

$4.50 → $0.25

Dec-18-18

Initiated

Ladenburg Thalmann

Buy

Dec-11-18

Initiated

Oppenheimer

Outperform

Nov-26-18

Upgrade

Piper Jaffray

Neutral → Overweight

Sep-21-18

Upgrade

JP Morgan

Underweight → Overweight

Jun-14-21 01:47PM	Were a good 18 months away before theres enough vaccine to stop COVID-19s worldwide spread: Epidemiologist Yahoo Finance Video
01:27PM	Novavax Vaccine Is Real Competition for Pfizer and Moderna Barrons.com
01:01PM	Novavax Achieves Positive Results for COVID-19 Vaccine Candidate NVX-Cov2373 During Trials SmarterAnalyst
12:56PM	Most of our vaccine will go to middle and low income countries: Novavax CEO Yahoo Finance Video
12:04PM	UPDATE 1-Novavax COVID-19 vaccine more than 90% effective in U.S. trial Reuters
11:45AM	Ethics have been pushed to the back amid COVID-19: Doctor Yahoo Finance Video
11:03AM	Is Novavax Stock A Buy On The Effectiveness Of Its Coronavirus Vaccine? Investor's Business Daily
10:56AM	Vaccine Stocks Slide After Novavax Shot Proves Highly Effective Bloomberg
10:55AM	Lordstown CEO & CFO resigns, Chipotle gets upgraded, Novavax reports 90% vaccine efficancy Yahoo Finance Video
09:56AM	Novavax Stock Yo-Yos After Biotech Says Covid Vaccine Protects Against Variants Investor's Business Daily
09:56AM	Novavax Stock Yo-Yoes After Biotech Says Covid Vaccine Protects Against Variants Investor's Business Daily
09:53AM	Novavaxs Study Showed Its Covid-19 Vaccine Works. Why Moderna Stock Is Down. Barrons.com
08:54AM	Novavax Stock Is Soaring Because a Study Showed Its Covid-19 Vaccine Works Barrons.com
08:11AM	Teslas Elon Musk Gives Bitcoin a Bounce, Just Not Enough of One Barrons.com
08:02AM	Lordstown Stock Is Sliding, Novavax Is Gaining and the Market Is Waiting for the Fed Barrons.com
07:35AM	AMC jumps more than 18%, other 'meme stocks' mixed Reuters
07:00AM	If a COVID Vaccine Becomes Seasonal, Watch Novavax: Here's 2 Ways to Trade It TheStreet.com
06:44AM	Long-awaited Novavax's COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection Benzinga
06:40AM	Novavax Stock Is Soaring Because a Study Showed Its Covid 19 Vaccine Works Barrons.com
06:29AM	Novavax's COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants Benzinga
06:12AM	Novavax reports COVID-19 vaccine was 90% effective in Phase 3 study MarketWatch
06:05AM	Novavax COVID-19 vaccine more than 90% effective in U.S. trial Reuters
06:00AM	Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial PR Newswire
06:00AM	Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial CNW Group
04:36AM	Premarket Movers Monday - Lordstown, Novavax, Riot Blockchain TheStreet.com
02:34AM	Novavax Soars As Its COVID-19 Vaccine Is Found 90% Effective, To Seek FDA OK Investing.com
02:20AM	Novavax COVID Vaccine Hits 90% Efficacy in Late-Stage Trial; Shares Leap TheStreet.com
Jun-13-21 08:00PM	Novavax vaccine trial shows 90% efficacy in combating Covid-19 Financial Times
Jun-12-21 06:08AM	Which Stocks Are the Biggest Losers From the FDA's COVID Vaccine Authorization Changes? Motley Fool
Jun-11-21 05:37PM	UPDATE 1-Novavax says COVID-19 vaccine shows immune response against Beta virus variant Reuters
04:05PM	Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine PR Newswire
Jun-10-21 12:07PM	Why Shares of Novavax Crashed 37.7% in May Motley Fool
06:06AM	Ditch Dogecoin: These Stocks Are Screaming Buys in June Motley Fool
Jun-09-21 02:50PM	Fertility is not going to be affected in any way by COVID-19 vaccine: Doctor Yahoo Finance Video +5.43%
11:30AM	Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report? Zacks
09:03AM	Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters PR Newswire
Jun-08-21 06:40PM	Novavax: Still a Compelling COVID-19 Play TipRanks
02:03PM	U.S. response to COVID-19 has a greater list of failures than accomplishments: Expert Yahoo Finance Video
10:30AM	Should You Worry About Novavax's Vaccine Delay? Motley Fool
Jun-07-21 04:05PM	Novavax to Participate in Panel at BIO Digital 2021 PR Newswire +6.57%
03:13PM	These Vaccine Latecomers Could Still Win Big. Here's How Motley Fool
02:33PM	Thought These 2 Nasdaq Vaccine Stocks Were Done? Think Again Motley Fool
01:45PM	U.S. should be very concerned as Delta variant spreads in Britain: Doctor Yahoo Finance Video
Jun-06-21 03:04PM	What Investors Should Know About Novavax's South Korea Expansion Motley Fool
Jun-05-21 07:31AM	Could Novavax Have a Clinical Trial Mutiny on Its Hands? Motley Fool
Jun-04-21 03:53PM	Novavax Stock Spikes as U.S. Releases Hold on Raw Materials for COVID-19 Vaccines Motley Fool +5.37%
03:20PM	Despite Setbacks, the Future Remains Bright for Novavax Stock InvestorPlace
02:50PM	'We still need to go even above and beyond the 70% threshold on vaccinations: Doctor Yahoo Finance Video
02:12PM	Biden partners with small businesses in COVID-19 vaccination push Yahoo Finance Video
09:38AM	How the pandemic spurred reform of clinical trials in drug industry Yahoo Finance
Jun-03-21 01:36PM	U.S. COVID-19 cases hits a new low but we still have gaps to close: Doctor Yahoo Finance Video
11:30AM	White House to allow AstraZeneca, Novavax, Sanofi to distribute COVID-19 shots how they see fit MarketWatch
09:36AM	Down 50%, Is Novavax Stock a Great Buy Now? Motley Fool
06:06AM	Dump Dogecoin: These Stocks Are Going to the Moon Motley Fool
Jun-02-21 04:10PM	Why Novavax Stock Soared Today Motley Fool +17.81%
02:15PM	Vaccine confidence has gone up significantly in communities of color: Doctor Yahoo Finance Video
09:41AM	Novavax Says Data From Its U.S. Phase 3 Trial Is Coming Soon Barrons.com
Jun-01-21 02:57PM	Moderna seeks full FDA approval for its COVID-19 vaccine Yahoo Finance Video
03:46AM	Novavax, Inc.'s (NASDAQ:NVAX) Path To Profitability Simply Wall St.
May-31-21 06:01AM	The Best Biotech Stocks to Buy With $500 Motley Fool
May-29-21 06:42AM	Got $5,000? Buy These 2 Stocks Instead of Dogecoin Motley Fool
May-28-21 01:43PM	Psychology of COVID-19 vaccine incentives will only go so far : Doctor Yahoo Finance Video
07:03AM	COVID Vaccine Update: Where J&J, AstraZeneca, Novavax, and Sinovac Stand Now Motley Fool
May-27-21 02:10PM	NJ lifting COVID-19 mandates is a good step in the right direction: Doctor Yahoo Finance Video
08:30AM	Novavax to Participate in Jefferies Virtual Healthcare Conference PR Newswire
May-26-21 02:52PM	Yesterday was first day dining activity exceeded pre-pandemic levels in the U.S.: OpenTable CEO Yahoo Finance Video
02:05PM	U.S. has a false sense of security right now on COVID-19: Doctor Yahoo Finance Video
02:03PM	Biden to intensify investigation into COVID-19 origin Yahoo Finance Video
May-25-21 03:13PM	Deepak Chopra on managing stress in post-covid world Yahoo Finance Video
02:44PM	Its the perfect moment to talk about getting kids vaccinated: Doctor Yahoo Finance Video
01:53PM	Has Novavax Lost the Vaccine Race to Moderna? Motley Fool
11:30AM	When Will We Have a Flu/COVID-19 Vaccine Combo? Motley Fool
05:51AM	Dump Dogecoin: Smart Investors Are Buying These Supercharged Stocks Motley Fool
May-24-21 05:03PM	Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update PR Newswire
02:28PM	United Airlines joins Uber, Lyft, and Shake Shack in COVID-19 vaccine push Yahoo Finance Video
01:51PM	Pfizer begins testing booster shot on fully vaccinated adults Yahoo Finance Video
12:13PM	Why Novavax Stock Is Rising Today Motley Fool
May-23-21 06:04AM	The Top Reason Novavax Could Still Be a Huge Winner in the COVID-19 Vaccine Market Motley Fool
May-22-21 12:39PM	Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea PR Newswire
12:20PM	Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea PR Newswire
11:31AM	How Bad Is Novavax's COVID Vaccine EUA Filing Delay? Motley Fool
07:01AM	Novavax Changes the Protocol for Its U.S. COVID Vaccine Study: Here's What You Should Know Motley Fool
06:13AM	2 Top Biotech Stocks to Buy for Summer 2021 Motley Fool
May-21-21 01:43PM	The U.S. is not maximizing access to COVID-19 vaccines: Doctor Yahoo Finance Video
08:53AM	Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration PR Newswire
May-20-21 01:58PM	A close eye must be kept on COVID-19 immunity: Doctor Yahoo Finance Video
10:47AM	The Battle Over Covid Vaccine Patents Begins What It Could Mean For Biotech Investor's Business Daily
05:04AM	Australia's CSL unable to simultaneously make Novavax, AstraZeneca vaccines Reuters
02:11AM	Big pharma and private equity seek healthy returns in Europe's east Reuters
02:00AM	FOCUS-Big pharma and private equity seek healthy returns in Europe's east Reuters
May-19-21 01:49PM	Theres always a concern' of another COVID-19 wave: Doctor Yahoo Finance Video
May-18-21 06:00AM	Here's Why This Top Stock Is a Buy on the Dip Motley Fool
05:21AM	Vaccine manufacturer Oxford Biomedica doubles sales forecasts as AstraZeneca ups orders Yahoo Finance UK
May-17-21 07:43AM	Buy-the-Dip Candidates: Jim Cramer Still Likes Disney Stock TheStreet.com +6.43%
06:06AM	5 Risky Stocks With 138% to 216% Upside, According to Wall Street Motley Fool
May-16-21 11:09PM	SK bioscience's COVID-19 vaccine plant in South Korea gets European nod Reuters
May-15-21 06:06AM	4 Large-Cap Stocks That Turned $200,000 Into $1 Million (or More) in 1 Year Motley Fool
06:02AM	Why Novavax's Pending COVID Vaccine Deal With the EU Raised Concerns Motley Fool
May-14-21 05:27PM	Novavaxs Long-Term Outlook Remains Intact, Says Analyst TipRanks +8.83%
04:06PM	Doctor: 'I will be wearing masks indoors for the foreseeable future Yahoo Finance Video

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
EVANS GARY C	Director	Jun 01	Sale	146.50	625	91,562	0	Jun 03 05:34 PM
Herrmann John A III	EVP, Chief Legal Officer	May 28	Option Exercise	14.83	2,895	42,932	3,170	Jun 02 04:59 PM
Herrmann John A III	EVP, Chief Legal Officer	May 28	Sale	149.14	2,895	431,748	275	Jun 02 04:59 PM
King Rachel K.	Director	May 19	Buy	139.64	700	97,748	2,800	May 21 05:06 PM
Glenn Gregory M	President, R&D	May 19	Sale	142.17	2,385	339,066	2,811	May 19 05:26 PM
Glenn Gregory M	President, R&D	May 17	Option Exercise	13.16	10,531	138,577	8,523	May 19 05:26 PM
Glenn Gregory M	President, R&D	May 17	Sale	133.98	5,712	765,267	2,811	May 19 05:26 PM
Trizzino John	EVP, CCO, CBO & Interim CFO	May 07	Sale	176.63	190	33,559	287	May 07 05:10 PM
Trizzino John	EVP, CCO, CBO & Interim CFO	May 05	Option Exercise	14.73	3,406	50,160	3,309	May 07 05:10 PM
Trizzino John	EVP, CCO, CBO & Interim CFO	May 05	Sale	185.46	3,022	560,471	287	May 07 05:10 PM
Herrmann John A III	EVP, Chief Legal Officer	Apr 30	Option Exercise	14.82	2,895	42,892	3,170	May 04 06:03 PM
Herrmann John A III	EVP, Chief Legal Officer	Apr 30	Sale	239.83	2,895	694,317	275	May 04 06:03 PM
Trizzino John	EVP, Chief Commercial Officer	Apr 07	Sale	178.03	191	34,004	287	Apr 07 05:09 PM
Trizzino John	EVP, Chief Commercial Officer	Apr 05	Option Exercise	34.01	3,404	115,771	3,308	Apr 07 05:09 PM
Trizzino John	EVP, Chief Commercial Officer	Apr 05	Sale	190.10	3,021	574,292	287	Apr 07 05:09 PM
Herrmann John A III	EVP, Chief Legal Officer	Mar 26	Option Exercise	14.82	2,894	42,886	3,169	Mar 30 06:10 PM
Herrmann John A III	EVP, Chief Legal Officer	Mar 26	Sale	186.80	2,894	540,609	275	Mar 30 06:10 PM
YOUNG JAMES F	Director	Mar 25	Option Exercise	8.96	47,500	425,438	57,500	Mar 25 06:41 PM
YOUNG JAMES F	Director	Mar 23	Option Exercise	46.00	10,000	460,000	20,000	Mar 25 06:41 PM
YOUNG JAMES F	Director	Mar 23	Sale	228.22	10,000	2,282,231	10,000	Mar 25 06:41 PM
MCMANUS MICHAEL A JR	Director	Mar 19	Sale	220.78	4,000	883,110	5,951	Mar 23 05:33 PM
Glenn Gregory M	President, R&D	Mar 17	Sale	218.86	2,423	530,304	2,811	Mar 17 06:35 PM
Glenn Gregory M	President, R&D	Mar 15	Option Exercise	109.95	10,531	1,157,843	8,523	Mar 17 06:35 PM
EVANS GARY C	Director	Mar 15	Option Exercise	19.52	24,500	478,330	40,599	Mar 17 06:36 PM
EVANS GARY C	Director	Mar 15	Sale	211.21	24,500	5,174,536	16,099	Mar 17 06:36 PM
Glenn Gregory M	President, R&D	Mar 15	Sale	198.60	5,712	1,134,400	2,811	Mar 17 06:35 PM
Trizzino John	EVP, Chief Commercial Officer	Mar 09	Sale	168.09	190	31,937	287	Mar 09 07:38 PM
Trizzino John	EVP, Chief Commercial Officer	Mar 05	Option Exercise	14.73	3,404	50,148	3,308	Mar 09 07:38 PM
Trizzino John	EVP, Chief Commercial Officer	Mar 05	Sale	163.46	3,021	493,824	287	Mar 09 07:38 PM
Herrmann John A III	EVP, Chief Legal Officer	Feb 26	Option Exercise	14.82	2,895	42,892	3,170	Mar 02 05:37 PM
Herrmann John A III	EVP, Chief Legal Officer	Feb 26	Sale	225.48	2,895	652,759	275	Mar 02 05:37 PM
Glenn Gregory M	President, R&D	Feb 18	Sale	269.57	2,434	656,134	2,811	Feb 18 06:59 PM
Glenn Gregory M	President, R&D	Feb 16	Option Exercise	13.16	10,531	138,577	8,523	Feb 18 06:55 PM
Glenn Gregory M	President, R&D	Feb 16	Sale	282.71	5,712	1,614,812	2,811	Feb 18 06:55 PM
Trizzino John	EVP, Chief Commercial Officer	Feb 09	Sale	324.50	194	62,953	287	Feb 09 07:40 PM
Trizzino John	EVP, Chief Commercial Officer	Feb 05	Option Exercise	14.73	3,406	50,160	3,309	Feb 09 07:40 PM
Trizzino John	EVP, Chief Commercial Officer	Feb 05	Sale	290.46	3,022	877,766	287	Feb 09 07:40 PM
Herrmann John A III	EVP, Chief Legal Officer	Feb 01	Option Exercise	18.15	15,022	272,724	15,297	Feb 03 05:37 PM
Herrmann John A III	EVP, Chief Legal Officer	Feb 01	Sale	241.50	15,022	3,627,789	275	Feb 03 05:37 PM
Trizzino John	EVP, CMO and CBO	Jan 07	Sale	124.17	506	62,830	287	Jan 07 07:08 PM
Trizzino John	EVP, CMO and CBO	Jan 05	Option Exercise	18.63	13,756	256,243	17,694	Jan 07 07:08 PM
Trizzino John	EVP, CMO and CBO	Jan 05	Sale	112.00	17,407	1,949,522	287	Jan 07 07:08 PM
YOUNG JAMES F	Director	Dec 31	Option Exercise	51.27	11,000	564,000	11,000	Jan 05 05:38 PM
DOUGLAS RICHARD	Director	Dec 31	Option Exercise	50.00	1,000	50,000	28,500	Jan 05 05:42 PM
YOUNG JAMES F	Director	Dec 31	Sale	113.09	11,000	1,244,014	0	Jan 05 05:38 PM
Erck Stanley C	President and CEO	Nov 16	Option Exercise	37.14	52,317	1,942,801	72,811	Nov 18 06:09 PM
Erck Stanley C	President and CEO	Nov 16	Sale	90.65	52,316	4,742,667	20,495	Nov 18 06:09 PM
Erck Stanley C	President and CEO	Oct 01	Sale	108.56	2	217	20,494	Oct 01 05:39 PM
Trizzino John	EVP, CBO and CFO	Sep 30	Sale	110.22	2,250	248,002	5,087	Oct 01 05:40 PM
Erck Stanley C	President and CEO	Sep 30	Sale	110.23	12,231	1,348,200	20,496	Oct 01 05:39 PM
Herrmann John A III	EVP, Chief Legal Officer	Sep 29	Sale	107.31	18,029	1,934,667	275	Sep 30 09:30 PM
Glenn Gregory M	President, R&D	Sep 29	Sale	107.02	19,949	2,134,844	1,561	Sep 30 09:29 PM
Trizzino John	EVP, CBO and CFO	Sep 29	Sale	107.29	18,321	1,965,630	7,337	Sep 30 09:28 PM
Erck Stanley C	President and CEO	Sep 29	Sale	107.80	4,112	443,267	32,727	Sep 30 09:27 PM
Erck Stanley C	President and CEO	Sep 28	Option Exercise	5.95	50,000	297,500	74,606	Sep 30 09:27 PM
Trizzino John	EVP, CBO and CFO	Sep 28	Option Exercise	5.95	29,600	176,120	53,008	Sep 30 09:28 PM
Glenn Gregory M	President, R&D	Sep 28	Option Exercise	5.95	25,000	148,750	46,510	Sep 30 09:29 PM
Herrmann John A III	EVP, Chief Legal Officer	Sep 28	Option Exercise	5.95	24,750	147,262	43,054	Sep 30 09:30 PM
Glenn Gregory M	President, R&D	Sep 28	Sale	110.30	25,000	2,757,456	21,510	Sep 30 09:29 PM
Herrmann John A III	EVP, Chief Legal Officer	Sep 28	Sale	110.30	24,750	2,729,879	18,304	Sep 30 09:30 PM
Trizzino John	EVP, CBO and CFO	Sep 28	Sale	110.30	25,000	2,757,456	25,658	Sep 30 09:28 PM
Erck Stanley C	President and CEO	Sep 28	Sale	110.30	25,000	2,757,456	36,839	Sep 30 09:27 PM
EVANS GARY C	Director	Aug 18	Option Exercise	31.02	10,500	325,700	332,479	Aug 20 06:09 PM
Glenn Gregory M	President, R&D	Aug 18	Option Exercise	33.56	55,921	1,876,525	57,760	Aug 20 06:14 PM
Herrmann John A III	EVP, Chief Legal Officer	Aug 18	Option Exercise	53.82	46,242	2,488,613	46,517	Aug 20 06:20 PM
MCMANUS MICHAEL A JR	Director	Aug 18	Option Exercise	27.60	8,000	220,800	17,951	Aug 20 06:22 PM
Trizzino John	EVP, CBO and CFO	Aug 18	Option Exercise	50.95	42,788	2,179,986	47,875	Aug 20 06:25 PM
Trizzino John	EVP, CBO and CFO	Aug 18	Sale	148.78	42,788	6,366,182	5,087	Aug 20 06:25 PM
MCMANUS MICHAEL A JR	Director	Aug 18	Sale	146.00	8,000	1,168,000	9,951	Aug 20 06:22 PM
Herrmann John A III	EVP, Chief Legal Officer	Aug 18	Sale	144.33	46,242	6,673,982	275	Aug 20 06:20 PM
Glenn Gregory M	President, R&D	Aug 18	Sale	145.20	55,921	8,119,860	1,839	Aug 20 06:14 PM
EVANS GARY C	Director	Aug 18	Sale	150.44	10,500	1,579,620	321,979	Aug 20 06:09 PM
Glenn Gregory M	President, R&D	Jun 18	Option Exercise	42.20	16,749	706,808	18,588	Jun 22 05:29 PM
Glenn Gregory M	President, R&D	Jun 18	Sale	59.53	16,749	997,103	1,839	Jun 22 05:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience